Elanco Animal Health (NYSE:ELAN) Releases Q2 2026 Earnings Guidance

Elanco Animal Health (NYSE:ELAN) issued an update on its second quarter 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.250-0.285 for the period, compared to the consensus estimate of 0.290. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.3 billion. Elanco Animal Health also updated its FY 2026 guidance to 1.030-1.090 EPS.

Elanco Animal Health Trading Up 2.4%

Shares of ELAN stock opened at $23.05 on Wednesday. Elanco Animal Health has a 12-month low of $9.42 and a 12-month high of $27.72. The company has a market capitalization of $11.46 billion, a P/E ratio of -48.02, a P/E/G ratio of 2.87 and a beta of 1.69. The firm has a 50-day moving average price of $23.82 and a 200 day moving average price of $23.29. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Research analysts forecast that Elanco Animal Health will post 1.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ELAN. Weiss Ratings upgraded shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, April 27th. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 18th. JPMorgan Chase & Co. boosted their price objective on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, February 19th. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Finally, Citigroup began coverage on shares of Elanco Animal Health in a report on Wednesday, April 15th. They set a “buy” rating and a $30.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and a consensus price target of $27.90.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ELAN. UBS Group AG boosted its holdings in Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock worth $331,669,000 after purchasing an additional 5,961,457 shares during the last quarter. Invesco Ltd. boosted its holdings in Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after purchasing an additional 3,690,735 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock worth $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Elanco Animal Health by 568.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,796,753 shares of the company’s stock worth $63,292,000 after purchasing an additional 2,378,455 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Elanco Animal Health by 48.0% during the third quarter. Northern Trust Corp now owns 4,291,618 shares of the company’s stock worth $86,433,000 after purchasing an additional 1,391,697 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.